Biotech
-
505AVXL Stock Ready To Make A Big Move
AVXL stock was a big winner for us here at Insider Financial back in 2015 when we caught the run from $1 to...
-
12.6KHandicapping CytoDyn’s (OTCMKTS: CYDY) Interim Readout
Powerful recommendation from DSMB Imminent on Leronlimab Numbers are not part of any Interim report unless a statistical penalty is taken A...
-
482Inspyr Therapeutics (NSPX): A Monster Runner
Inspyr Therapeutics (NSPX) has turned into a monster runner and a massive win for our subscribers that got our alert last Friday....
-
375Northwest Bio About To Cross The Finish Line
It has been a long 13-year wait for shareholders of Northwest Bio, but top-line data is imminent. The database for the Phase...
-
20.5KENZC and BioClonetics: A Perfect Merger
President Trump’s hospitalization for COVID-19 has shed the spotlight on the most important aspect in the treatment of the coronavirus –...
-
378Innovation Pharmaceuticals: A Cheap COVID-19 Play
Innovation Pharmaceuticals is a small-cap biotech that we have covered here at Insider Financial beginning when it was originally Cellceutix Corp. ...
-
12.3K1All Eyes On CytoDyn Now That Trump Has COVID-19
Just now, markets are waking up to the news that President Donald Trump and First Lady Melanie have tested positive for COVID-19....
-
330PharmaCyte Biotech Climbing Back Up The Charts
Shares of PharmaCyte Biotech are climbing back up the charts after being on a downtrend for the past year. The stock hit highs of...
-
409Compass Pathways Investors Need To Look At MMEDF
Compass Pathways is a new IPO that shot up the NASDAQ charts over the past week. Investors are jumping on the stock because...
-
6441RLFTF Is Tremendously Undervalued
RLFTF remains one of our favorite COVID-19 plays here at Insider Financial. In our last profile of the company, we focused on...